



Prof. G. Zuliani



- Hemoptysis is the expectoration of blood, that can range from *blood-streaking of sputum* (Hemoptoe) to the presence of *gross blood* in the absence of any accompanying sputum.
- The term *massive hemoptysis* is reserved for potentially life-threatening bleeding; it has been defined by a number of different criteria, more often as *more than 600 ml of blood over a 24 hour period.*

- 1000 ml of blood in the alveolar space is sufficient to cause significant hindrance to the oxygen transfer.
- Massive hemoptysis accounts for only 1.5% of all hemoptysis.
- The majority of hemoptysis originates from the *bronchial arteries* (about 90%)

VASCULAR ORIGIN OF HEMOPTYSIS

- Blood traversing the lungs can arrive from:
 - pulmonary arteries
 - bronchial arteries
- Virtually, the entire *cardiac output* courses through the *low-pressure* pulmonary arteries and arterioles to be oxygenated in the pulmonary capillary bed
- In contrast, the *bronchial arteries* carry only a small portion of the cardiac output, but are under much *higher systemic pressure*

VASCULAR ORIGIN OF HEMOPTYSIS

- Despite the quantitatively smaller contribution of the bronchial circulation to pulmonary blood flow, the *bronchial arteries* are generally a much more important source of hemoptysis than the pulmonary circulation
- In addition to being perfused at a higher pressure, they also supply blood to the airways and to lesions within the airways

- The total mortality rate related to hemoptysis is influenced by:
- 1. Malignant etiologies
- 2. Bleeding rate
- The coexistence of hemoptysis over 1000 ml/24hr and malignancy in the same patient brought the mortality rate to about 80%.

DIFFERENTIAL DIAGNOSIS OF HEMOPTYSIS

- Before assuming a *lower respiratory source* of the bleeding, it is always important to consider whether the blood may be coming from a *non-pulmonary source*, such as the *upper airways* or the *gastrointestinal tract*
- Alkaline pH, foaminess, or the presence of pus may sometimes suggest the lungs as the primary source of bleeding rather than the stomach.

1. Airways diseases

- The most common source of hemoptysis is airways disease:
 - Inflammatory diseases: such as acute bronchitis or bronchiectasis
 - Neoplasms: including primary bronchogenic carcinoma, endobronchial metastatic carcinoma or bronchial carcinoid
 - Foreign body & Airway trauma
 - Kaposi's sarcoma: in patients with AIDS, involving the airways and/or the pulmonary parenchyma
 - Fistula between a vessel and the tracheo-bronchial tree:
 - fistulas between the aorta and the airway are associated with aneurysms of the thoracic aorta; are fatal if not diagnosed and surgically treated

1. Airways diseases

- Bronchitis
- Bronchiectasis
- COPD
- Bronchogenic carcinoma are common causes of hemoptysis.





2. Pulmonary parenchymal diseases

- Infections: especially tuberculosis, pneumonia, aspergilloma, and lung abscess
 - Hemoptysis, which can be life-threatening, complicates the course of 50-85 percent patients with an Aspergilloma



- Tuberculosis can cause massive hemoptysis through multiple mechanisms
 - Active cavitary or non-cavitary lung disease can cause small or large amounts of bleeding
 - Active disease can cause sudden *rupture of a Rasmussen's aneurysm* (aneurysm of the pulmonary artery that slowly expands into an adjacent cavity because of inflammatory erosion of the external vessel wall until it bursts)



2. Pulmonary parenchymal diseases

- Inflammatory or immune disorders
 - Goodpasture's syndrome, Wegener's granulomatosis, pulmonary hemosiderosis, lupus pneumonitis,
- Coagulopaties
 - thrombocytopenia or use of anticoagulants
- latrogenic: percutaneous or transbronchial lung biopsy. Hemoptysis, which is usually minor and transient, occurs in five to 10% of percutaneous lung biopsies (but massive hemorrhage and death have also been reported)

2. Other cause of pulmonary parenchymal hemorrhage

Cocaine-induced pulmonary hemorrhage

 Hemoptysis has been described in about 6% of habitual smokers of free-base cocaine ("crack") and has been associated with diffuse alveolar hemorrhage



Catamenial hemoptysis

 Hemoptysis, in women, that is recurrent and coincident with menses. The cause is intrathoracic *endometriosis*, usually involving the pulmonary parenchyma but occasionally affecting the airways

3. Pulmonary vascular disorders

- Pulmonary embolism (infarction)
- Pulmonary A-V malformation, either with or without underlying *Rendu-Osler-Weber* syndrome




- Elevated pulmonary capillary pressure
 - mitral valve stenosis
 - significant left ventricular failure
 - congenital heart diseases
 - severe pulmonary hypertension
- latrogenic
 - pulmonary artery perforation from a Swan-Ganz catheter

0 2008 Elsevier Inc.

Hereditary hemorrhagic telangiectasia: ROW



Fig. 2. Telangiectasia en mucosa labial.





4. Cryptogenic hemoptysis

- Depending upon the study, up to **30%** of patients with hemoptysis have NO cause identified even after careful evaluation
- In a series of patients with "cryptogenic" hemoptysis, the prognosis was generally good, and most patients had resolution of bleeding within six months of evaluation

Adelman M et al. Cryptogenic hemoptysis. Clinical features, bronchoscopic findings, and natural history in 67 patients. Ann Intern Med

TABLE 1 Differential Diagnosis of Hemoptysis	sis			1
Source other than the lower respiratory tract Upper airway (nasopharyngeal) bleeding Gastrointestinal bleeding Tracheobronchial source	Pulmonary parenchymal source Lung abscess Pneumonia Tuberculosis Mycetoma ("fungus ball")	Primary vascular source Arteriovenous malformation Pulmonary embolism Elevated pulmonary venous pressure (especially mitral stenosis)	oressure	
Neoplasm (bronchogenic carcinoma, endobronchial metastatic tumor, Kaposi's sarcoma, bronchial carcinoid) Bronchitis (acute or chronic)	Goodpasture's syndrome Idiopathic pulmonary hemosiderosis Wegener's granulomatosis	Pulmonary artery rupture secondary to balloon-tip pulmonary artery catheter manipulation Miscellaneous and rare causes	condary t ry cathet uses	ter
Bronchiectasis	Lupus pneumonitis	Pulmonary endometriosis		
Broncholithiasis Airway trauma Foreign body	Long contusion	Systemic coagulopathy or use of anticoagulants or thrombolytic agents	e of lytic ager	nts
Adapted with permission from Weinberger SE. Principles of pulmonary medicine. 3d ed. Philadelphia: Saunders, 1998.	ciples of pulmonary medicine. 3d ed. Philadelphi	a: Saunders, 1998.		
1254 American Family Physician	www.aafp.org/afp	Table 2 - Distribution of the infectious causes ofhemoptysis in 50 patients admitted to the pulmonologyward of the Otávio de Freitas General Hospital betweenJuly of 2005 and February of 2006.	ectious caus o the pulmon I Hospital bet	ses of iology tween
		Underlying diagnosis	r L	0/0
		ABPA	-	2.6
		Lung absccss		2.6
		Bronchiectasis	19 4	48.7
		Upper respiratory tract infection Lower respiratory tract infection	- 0	5.2
		Mycetoma		20.5
		Community-acquired pneumonia	e	7.7
		Active pulmonary tuberculosis		10.3
		Total ADDA - Il	39 1	00
		ABLA. allergie protieriopulitiorialy aspergillosis	aspergiiloais.	

EVALUATION OF HEMOPTYSIS

- The evaluation should begin with the initial history and *physical examination* supplemented by *chest radiograph*
- Important features of the history include: age, smoking history, duration of hemoptysis, and association with symptoms of acute bronchitis or exacerbation of chronic bronchitis

TABLE 3 Diagnostic Clues in Hemoptysis: Physical History	story
Clinical clues	Suggested diagnosis*
Anticoagulant use	Medication effect, coagulation disorder
Association with menses	Catamenial hemoptysis
Dyspnea on exertion, fatigue, orthopnea, paroxysmal nocturnal dyspnea, frothy pink sputum	Congestive heart failure, left ventricular dysfunction, mitral valve stenosis
Fever, productive cough	Upper respiratory infection, acute sinusitis, acute bronchitis, pneumonia, lung abscess
History of breast, colon, or renal cancers	Endobronchial metastatic disease of lungs
History of chronic lung disease, recurrent lower respiratory track infection, cough with copious purulent sputum	Bronchiectasis, lung abscess
HIV, immunosuppression	Neoplasia, tuberculosis, Kaposi's sarcoma
Nausea, vomiting, melena, alcoholism, chronic use of nonsteroidal anti-inflammatory drugs	Gastritis, gastric or peptic ulcer, esophageal varices
Pleuritic chest pain, calf tenderness	Pulmonary embolism or infarction
Tobacco use	Acute bronchitis, chronic bronchitis, lung cancer, pneumonia
Travel history	Tuberculosis, parasites (e.g., paragonimiasis, schistosomiasis, amebiasis, leptospirosis), biologic agents (e.g., plague, tularemia, T2 mycotoxin)
Weight loss	Emphysema, lung cancer, tuberculosis, bronchiectasis, lung abscess, HIV
*—Arranged from most to least common diagnosis for each clinical clue.	ical clue.
Information from references 4, 5, 17, and 18.	
October 1, 2005 • Volume 72, Number 7	www.aafp.org/afp American Family Physician 1255

October 1, 2005 • Volume 72, Number 7

www.aafp.org/afp

American Family Physician 1255

Physical examination

- Telangiectasias suggests R-O-W disease
- Skin rash may be suggestive of vasculitis
- Splinter hemorrhages suggest endocarditis or vasculitis
- **Clubbing** is non-specific
- Cardiac murmurs raise the question of congenital heart disease, endocarditis with septic emboli, or, when a diastolic rumble or opening snap is present, mitral stenosis
- The legs should be examined carefully for possible deep venous thrombi (eco-doppler)

EVALUATION OF HEMOPTYSIS

- NO immediate further work-up is indicated if the clinical picture IS NOT suggestive of a lung carcinoma:
 - negative chest radiograph
 - age <40 years</p>
 - no smoking history
 - hemoptysis < 1 week duration</p>
 - suggestive of acute bronchitis (blood streaking superimposed upon purulent sputum)
- The patient should be treated for bronchitis and observed for recurrence of hemoptysis following improvement in purulent sputum production

EVALUATION OF HEMOPTYSIS

Low-risk patients with normal chest radiographs can be treated on an outpatient basis with close monitoring and appropriate oral antibiotics, if medication is clinically indicated.

American Family Physician 1253

Information from references 4, 17, and 18.

TABLE 2 Differentiating Features of Hemoptysis and Hematemesis	Hematemesis	Presence of nausea and vomiting	Gastric or hepatic disease Asphyxia unusual	Rarely frothy Coffee ground appearance Brown to black	Acidic pH hages Mixed with food particles
TABLE 2 Differentiating Fe and Hematemesis	Hemoptysis	History Absence of nausea and vomiting	Lung disease Asphyxia possible Sputum examination	Frothy Liquid or clotted appearance Bright red or pink	Laboratory Alkaline pH Mixed with macrophages and neutrophils

Diagnostic Studies

- 1. Sputum Examination
- 2. Chest Radiography
- 3. Bronchoscopy
- 4. CT HRCT
- 5. Angiography

Normal or no change from Bronchitis, upper respiratory infection, sinusitis, pulmonary baseline baseline embolism Patchy alveolar infiltrates Bleeding disorders, idiopathic pulmonary hemosiderosis, Goodpasture's syndrome *-Arranged from most to least common diagnosis for each clinical clue. *-Arranged from references 4 and 17.	Mass lesion, nodules, Carcinoma, metastatic disease, Wegener's granulomatosis, granulomas septic embolism, vasculitides
ifiltrates	iental infiltrates
nass ifiltrates	ates
ates nass ifiltrates	infiltrates ly or mass ntal infiltrates
ed distribution ates nass nfiltrates	ncreased scular distribution infiltrates y or mass ntal infiltrates
<i>ling</i> ed distribution ates nass filtrates	<i>In finding</i> ncreased scular distribution infiltrates iy or mass ntal infiltrates

October 1, 2005 • Volume 72, Number 7

www.aafp.org/afp

EVALUATION OF HEMOPTYSIS

- Further evaluation is indicated if the patient has risk factors for carcinoma or if the hemoptysis does not occur in the setting of acute bronchitis
- Bronchoscopy is the preferred next procedure in those patients with risk factors for tumor or chronic bronchitis
- On the other hand, HRCT is the preferred next procedure in patients at lower risk for tumor or chronic bronchitis, but with a history or radiograph suggestive of <u>bronchiectasis</u> or an <u>arteriovenous</u> <u>malformation.</u>


DIAGNOSTIC PROCEDURES

• Bronchoscopy

- often considered in patients with hemoptysis and normal or non-localizing CXR to rule out endobronchial malignancy
- performed *early in the evaluation*, while the patient is still bleeding, provides the highest yield for localizing the bleeding site
- Risk factors predicting those individuals most likely to have **tumor** found on bronchoscopy include:
 - Male sex
 - Older age, greater than 50 years
 - Smoking history greater than 30 pack/year
 - Duration of hemoptysis greater than one week



Figure 3. Bronchoscopic image of the main carina and the bilateral polypoid lesions throught both left and right main bronchus.



A pink polypoid mass on the bronchial musosa

Arteriography

- If the patient continues to bleed and the source is still unknown, *Arteriography* should next be performed, since it may be useful for diagnosis and therapy too
- Since the majority of massive bleeds arise from the bronchial circulation, *bronchial arteriography* has a higher yield than arteriography of the pulmonary or systemic arterial beds
- When the *pulmonary arterial circulation* is the source, the most common underlying conditions are pulmonary A-V malformations, Rasmussen's aneurysms or iatrogenic pulmonary artery tears

CT scan of the chest

- Use of early chest CT has been advocated to help localize the bleeding site and diagnose the cause
- CT scan may suggest one of several diagnoses such as: bronchiectasis, lung abscess, and mass lesions including cancer, mycetomas, and A-V lesions
- It may also help in the acute setting to guide arteriography or bronchoscopy to the regions of highest yield
- The disadvantage of chest CT is that it may require temporary movement of an unstable patient

Bronchoscopy versus HRCT

- Bronchoscopy and HRCT are, in many ways, complementary studies, each with specific advantages in certain clinical situations
- In one study of 91 patients with hemoptysis, HRCT demonstrated all tumors seen by bronchoscopy as well as, several which were beyond bronchoscopic range. On the other hand, HRCT could not detect bronchitis or subtle mucosal abnormalities which could be seen by Bronchoscopy
- In another report of 57 patients, HRCT was particularly useful in diagnosing *bronchiectasis and aspergillomas*, while Bronchoscopy was diagnostic of *bronchitis and mucosal lesions* such as Kaposi's sarcoma


TABLE 6 Diagnostic Clues in Hemoptysis: Laboratory Tests	:: Laboratory Tests
Test	Diagnostic findings
White blood cell count and differential Hemoglobin, hematocrit	Elevated cell count and differential shifts may be present in upper and lower respiratory tract infections Decreased in anemia
Platelet count	Decreased in thrombocytopenia
Prothrombin time, International Normalized Ratio, partial thromboplastin time	Increased in anticoagulant use, disorders of coagulation
Arterial blood gases	Hypoxia, hypercarbia
D-dimer	Elevated in pulmonary embolism
Sputum Gram stain, culture, acid-fast bacillus smear and culture	Pneumonia, lung abscess, tuberculosis, mycobacterial infections
Sputum cytology	Neoplasm
Purified protein derivative skin test	Positive increases risk for tuberculosis
Human immunodeficiency virus test	Positive increases risk for tuberculosis, Kaposi's sarcoma
Erythrocyte sedimentation rate	Elevated in infection, autoimmune disorders (e.g., Wegener's syndrome, systemic lupus erythematosus, sarcoid, Goodpasture's syndrome), may be elevated in neoplasia
October 1, 2005 • Volume 72, Number 7	www.aafp.org/afp American Family Physician 1253

Acute management of hemoptysis

- Initial priorities are insuring adequate airway protection, ventilation, and cardiovascular function (ABC)
- Possible *coagulation disorders* should be rapidly reversed (PT, aPTT, platelet count)
- Patients with poor gas exchange, rapid ongoing hemoptysis, hemodynamic instability, or severe shortness of breath should be *orally intubated* with a large bore endotracheal tube (size 8.0 or greater)

Use of bronchoscopy in acute management of hemoptysis

- A bronchoscopic option for protecting the nonbleeding lung is *Balloon Tamponade* of the bleeding site, involving placement of a *Fogarty balloon catheter* in the segmental or sub-segmental bronchus leading to the bleeding site
- The balloon is left inflated for 24 to 48 hours, and the patient is then observed for rebleeding with the balloon deflated for several hours
- There is a potential risk of ischemic mucosal injury and post-obstructive pneumonia, but these complications have not been reported




Use of bronchoscopy in acute management of hemoptysis

- Bronchoscopic techniques used to slow or stop bleeding have included *lavage with saline* and application of *topical epinephrine* (1:20.000), *vasopressin, thrombin or a fibrinogen-thrombin combination*
- None of these methods has been tested in controlled trials (!)
- If bronchoscopy visualizes a localized bleeding mucosal lesion, *laser therapy or electrocautery* may be considered, if available

Protection of the non-bleeding lung

- If the location or side of bleeding is known, placing the bleeding lung in a dependent position may prevent blood spillage into the non-bleeding lung: *place the patient on lateral decubitus toward the site of bleeding*
- Selective intubation: an alternative strategy involves placement of a typical, *single lumen endotracheal tube* into either the right or left mainstem bronchus. This approach is less practical when the right lung is bleeding, because selective intubation of the left mainstem bronchus may be quite difficult
- A third alternative is the placement of a *double lumen endotracheal tube* specially designed for selective intubation of the right or left mainstem bronchi



Arteriographic embolization

- The other option for the patient who continues to bleed is *Arteriographic Embolization*, either as "semi-definitive" treatment or as a bridge to elective surgery
- In the hands of experienced angiographers, embolization successfully stops bleeding more than 85% of the time
- Unfortunately, embolization is only "semi-definitive," because *re-bleeding occurs in 10-20%* of patients over the next 6-12 months
- Late re-bleeding may be due to incomplete embolization, revascularization, or recanalization.




Figure 2 Use of selective bronchial artery embolisation to control massive haemoptysis. (A) Bronchial angiogram showing common trunk and left sided abnormal circulation pre-embolisation, and (B) post-embolisation angiogram showing the left bronchial artery and successful embolisation of abnormal vessels.

Surgery

- Patients with lateralized uncontrollable bleeding should be assessed early for possible surgery
- Contraindications to surgery include: severe underlying pulmonary disease (advanced K), active TBC, diffuse underlying lung disease (cystic fibrosis, multiple A-V Ms, multifocal bronchiectasis), and diffuse alveolar hemorrhage
- Morbidity and mortality are significantly greater with emergent surgery for persistent massive bleeding compared with elective surgery
- In most series of emergent therapy, surgical mortality for treatment of massive hemoptysis is high (approximately 20%)

